Atovaquone is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Camber Pharmaceuticals, Inc.. The primary component is Atovaquone.
| Product ID | 31722-629_525cd202-a971-44fb-829b-7cabcb0e40e3 |
| NDC | 31722-629 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Atovaquone |
| Generic Name | Atovaquone |
| Dosage Form | Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-10-11 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA210692 |
| Labeler Name | Camber Pharmaceuticals, Inc. |
| Substance Name | ATOVAQUONE |
| Active Ingredient Strength | 750 mg/5mL |
| Pharm Classes | Antimalarial [EPC],Antiprotozoal [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2018-10-11 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | ANDA |
| Application Number | ANDA210692 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2018-10-11 |
| Ingredient | Strength |
|---|---|
| ATOVAQUONE | 750 mg/5mL |
| SPL SET ID: | 2445304e-4b4e-4358-b098-31f3c49c52ef |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0121-0888 | Atovaquone | Atovaquone |
| 0121-0898 | Atovaquone | Atovaquone |
| 0121-1796 | Atovaquone | Atovaquone |
| 0904-7064 | Atovaquone | Atovaquone |
| 16714-900 | atovaquone | atovaquone |
| 31722-629 | Atovaquone | Atovaquone |
| 50268-086 | Atovaquone | Atovaquone |
| 51407-642 | Atovaquone | Atovaquone |
| 60687-534 | Atovaquone | Atovaquone |
| 65162-693 | ATOVAQUONE | ATOVAQUONE |
| 66689-062 | Atovaquone | Atovaquone |
| 66993-062 | Atovaquone | atovaquone |
| 68180-282 | Atovaquone | Atovaquone |
| 68462-421 | atovaquone | atovaquone |
| 70166-488 | Atovaquone | Atovaquone |
| 10702-223 | Atovaquone Oral Suspension | Atovaquone |
| 0173-0547 | MEPRON | atovaquone |
| 0173-0665 | MEPRON | atovaquone |